Relmada In-Licenses Psilocybin Program from Arbormentis

 Relmada In-Licenses Psilocybin Program from Arbormentis

Relmada In-Licenses Psilocybin Program from Arbormentis

Shots:

  • Arbormentis to receive $51M upfront in cash and equity in addition to $150M as milestone related to pre-specified development and commercialization milestones along with royalties on any commercialized therapy resulting from the collaboration
  • Relmada acquires the development & commercial rights for psilocybin and derivate program from Arbormentis in all Ex-Asia countries, including the US & EU. Additionally, companies collaborate to develop new therapies targeting neurological and psychiatric disorder
  • Relmada’s REL-1017 is currently in P-III trial for depression & results is expected from the human abuse potential study for REL-1017 in July’21

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Relmada

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post